Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245678 | 0.74 | — | — | |
| SCHEMBL22260360 | 0.68 | KDM4E (0.30) | ALDH1A1 | |
| SCHEMBL24235870 | 0.68 | ADORA2A (0.35) | ALDH1A1MEN1KMT2AADORA2AADORA1 | |
| SCHEMBL11098685 | 0.67 | ADORA2A (0.45) | ALDH1A1MEN1KMT2AADORA2AADORA1 | |
| SCHEMBL12246250 | 0.67 | ALDH1A1 (0.38) | ALDH1A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL7519857 | 0.66 | MAPK1 (0.66) | ALDH1A1MEN1KMT2AADORA2ASMN1; SMN2 | |
| SCHEMBL23730962 | 0.66 | CYP3A4 (0.45) | ALDH1A1MEN1KMT2AADORA2APOLB | |
| SCHEMBL21126208 | 0.65 | CDK1 (0.50) | ALDH1A1MEN1KMT2AADORA2AADORA1 | |
| SCHEMBL18289528 | 0.65 | CDK2 (0.54) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL13531642 | 0.64 | MET (0.35) | ALDH1A1MEN1KMT2AMETSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240010639-A1 | TRIAZINE DIONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-01-11 | — | — | US | disclosed |
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Pharmaceuticals, Inc. | 2022-02-03 | — | — | US | disclosed |
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| WO-2020121123-A2 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Biopharma, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-20180215729-A1 | NK 1 ANTAGONISTS | OPKO HEALTH, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215729-A1 | NK 1 ANTAGONISTS | OPKO HEALTH, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9969711-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969711-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20120295879-A1 | NK1 Antagonists | OPKO HEALTH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-8163707-B2 | 4′-allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8026364-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026364-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100190759-A1 | NK 1 ANTAGONISTS | OPKO HEALTH, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190759-A1 | NK 1 ANTAGONISTS | OPKO HEALTH, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7709641-B2 | Neurokinin-1, substance P (NK1); serotonin reuptake inhibitors; for treating emesis, depression, anxiety and cough | OPKO HEALTH, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | PNP, TYMP, HAVCR2 | ALDH1A1 2803/4885MEN1 3294/4885KMT2A 4179/4885 |
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | ALDH1A1 972/4885MEN1 4175/4885KMT2A 2924/4885 |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | NME2, HAVCR2, ENTPD5 | ALDH1A1 888/4885MEN1 4555/4885KMT2A 4030/4885 |
| US-20100190759-A1 | NK 1 ANTAGONISTS | BDKRB1, PROKR1, NPSR1 | ALDH1A1 825/4885MEN1 1232/4885KMT2A 1406/4885 |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | CCNI, CCNA1, CDK1 | ALDH1A1 770/4885MEN1 4441/4885KMT2A 3869/4885 |
| US-20120295879-A1 | NK1 Antagonists | NPSR1, GRPR, PROKR1 | ALDH1A1 1238/4885MEN1 1114/4885KMT2A 2039/4885 |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | ASAH2, MAN2B1, NNT | ALDH1A1 1148/4885MEN1 168/4885KMT2A 2094/4885 |
| US-20180215729-A1 | NK 1 ANTAGONISTS | BDKRB1, PROKR1, NPSR1 | ALDH1A1 825/4885MEN1 1232/4885KMT2A 1406/4885 |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | UNG, DUT, DPYD | ALDH1A1 972/4885MEN1 4175/4885KMT2A 2924/4885 |
| US-20240010639-A1 | TRIAZINE DIONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | MYLK2, TNNT2, TNNC1 | ALDH1A1 1551/4885MEN1 957/4885KMT2A 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.